Cargando…

Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression

BACKGROUND: To clarify the effects of cylcin E1 expression on HCC tumor progression, we studied the expression of cyclin E1 and inhibitory efficacy of regorafenib and sorafenib in HCC cells, and investigated a potential therapy that combines regorafenib treatment with cyclin E1 inhibition. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jianliang, Huang, Fei, Yao, Zhicheng, Jia, Changchang, Xiong, Zhiyong, Liang, Hao, Lin, Nan, Deng, Meihai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660968/ https://www.ncbi.nlm.nih.gov/pubmed/31349793 http://dx.doi.org/10.1186/s12964-019-0398-3

Ejemplares similares

Serum exosomal long noncoding RNAs lnc-FAM72D-3 and lnc-EPC1-4 as diagnostic biomarkers for hepatocellular carcinoma
por: Yao, Zhicheng, et al.
Publicado: (2020)

BDH2 is downregulated in hepatocellular carcinoma and acts as a tumor suppressor regulating cell apoptosis and autophagy
por: Liang, Hao, et al.
Publicado: (2019)

Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer
por: Song, Xiangping, et al.
Publicado: (2020)

Induction of Apoptosis, Inhibition of MCL-1, and VEGF-A Expression Are Associated with the Anti-Cancer Efficacy of Magnolol Combined with Regorafenib in Hepatocellular Carcinoma
por: Chen, Cheng-Hsien, et al.
Publicado: (2021)

Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics
por: Choudhary, Gaurav S., et al.
Publicado: (2015)

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models
por: Cucarull, Blanca, et al.
Publicado: (2020)

The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis
por: Yang, Jiarui, et al.
Publicado: (2021)

Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction
por: Schulze-Bergkamen, Henning, et al.
Publicado: (2006)

Identification of miRNAs as diagnostic and prognostic markers in hepatocellular carcinoma
por: Liang, Hao, et al.
Publicado: (2021)

Laparoscopic RFA with splenectomy for hepatocellular carcinoma
por: Hu, Kunpeng, et al.
Publicado: (2016)

Prognostic and Clinicopathological Value of PINX1 in Various Human Tumors: A Meta-Analysis
por: Liang, Hao, et al.
Publicado: (2018)

The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer
por: Stewart, Michelle L., et al.
Publicado: (2010)

LRH-1 drives hepatocellular carcinoma partially through induction of c-myc and cyclin E1, and suppression of p21
por: Xiao, Lijia, et al.
Publicado: (2018)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
por: Tibes, Raoul, et al.
Publicado: (2019)

Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice
por: Pieters, Tim, et al.
Publicado: (2021)

DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
por: Li, Yangling, et al.
Publicado: (2020)

Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Huang, Jingjun, et al.
Publicado: (2022)

Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis
por: Chang, Yu-Chan, et al.
Publicado: (2022)

Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib
por: Wang, Haochen, et al.
Publicado: (2022)

Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells
por: Liao, Mingmei, et al.
Publicado: (2011)

Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression
por: Duan, Yujie, et al.
Publicado: (2016)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
por: Li, Yangling, et al.
Publicado: (2022)

Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice
por: Weng, Mao-Chi, et al.
Publicado: (2018)

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
por: Zhang, Shun, et al.
Publicado: (2022)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis
por: Murphy, Á. C., et al.
Publicado: (2013)

MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib
por: Young, Adelaide I. J., et al.
Publicado: (2016)

CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma
por: Zheng, Adi, et al.
Publicado: (2019)

SPOP suppresses prostate cancer through regulation of CYCLIN E1 stability
por: Ju, Lin-Gao, et al.
Publicado: (2018)

Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells
por: Bhat, Mamatha, et al.
Publicado: (2016)

DEPDC1 promotes cell proliferation and suppresses sensitivity to chemotherapy in human hepatocellular carcinoma
por: Zhou, Chao, et al.
Publicado: (2019)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Early experience of seven hepatocellular carcinoma cases treated with regorafenib
por: Uchikawa, Shinsuke, et al.
Publicado: (2018)

The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib
por: Zhuo, Jianyong, et al.
Publicado: (2021)

Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Hou, Jing-Yu, et al.
Publicado: (2022)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
por: Liu, Junjie, et al.
Publicado: (2022)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jj35l0sjhp9ir79v12c16sgr9l